Immundnz collaborates with the group of Dr. Kathryn Hentges from University of Manchester in a research project to apply machine learning on cell-based immunological assay design. Immundnz performs in vitro assays to test the mechanism and effect of therapeutics on the immune system and to test the potential immunological risk of therapeutics. A battery of assays is performed in this, generating lots of data. In the collaborative project, this data will be used to train a machine learning model by predicting which therpeutics and assays will be consistent through small scale and large scale assay formats. Ultimately, if the model is accurate in predicting theapeutic and assay consistency, Immundnz will incorporate it as part of its services. (https://www.research.manchester.ac.uk/portal/Kathryn.Hentges.html)
How Could Immunity Against SARS-Cov-2 Last Up To More Than Six Months?
Things you need to know about Immune checkpoint functional assays
Everything You Should Know about New COVID-19 Strain
Lipid Droplets: They Work As Intracellular Bacteria-Fighting Machines
Malaria Parasite Changes Their Genes’ Role to Hide in Human Blood